No bombshells expected in second-quarter resultsRadiopharmacy market leader Syncor International has shuffledits top management lineup after the surprise resignation of CEOGene McGrevin on July 1. COO Robert Funari was tapped to take
Radiopharmacy market leader Syncor International has shuffledits top management lineup after the surprise resignation of CEOGene McGrevin on July 1.
COO Robert Funari was tapped to take McGrevin's place as CEOof the Chatsworth, CA, firm. McGrevin's role as chairman and CEOof P.E.T.Net, a fledgling regional PET cyclotron joint venturebetween Syncor and CTI Services of Knoxville, TN, is being filledon an interim basis by Syncor CFO Michael Mikity.
With the exception of McGrevin's absence, the new lineup isnot all that different from changes set to take effect later thisyear (SCAN 1/31/96). Syncor founder and board chairman Monty Fuhad planned to become chairman emeritus, turning his job overto McGrevin, who was to be replaced as CEO by Funari. FollowingMcGrevin's resignation, Fu will continue as chairman while assuminga more active role in a multimillion-dollar effort to expand Syncor'soverseas radiopharmacy network, Funari said.
The reason for McGrevin's sudden exit is unclear. A July 3memo from Fu to Syncor employees mentioned only that McGrevinhad resigned to pursue other business opportunities.
Although declining to comment on why McGrevin resigned, Funarisaid in an interview with SCAN that Syncor's second-quarter financialreport, scheduled for release on July 25, will be consistent withthe firm's positive first-quarter results.
"There are no financial time bombs here," he said.
Funari was executive vice president and general manager ofthe drug division of McKesson, a $12 billion pharmaceutical distributioncompany in San Francisco, before McGrevin recruited him as COOin August 1993. Funari was also formerly president of Pharmaseal,a medical-products division of Baxter International.
Funari promised to stay the course by following strategic objectivesset last year. They led to the expansion of Syncor's PET radioisotopebusiness through P.E.T.Net and improved supplier relations, suchas deals completed earlier this year with Mallinckrodt Medicalin St. Louis and Amersham Healthcare/Medi-Physics in ArlingtonHeights, IL (SCAN 4/24/96 and 6/5/96).
"I see progress on both those fronts as well as the waveof new oncology products that we see coming toward nuclear medicine.We're bullish about the future," he said.
What a New Mammography Study Reveals About BMI, Race, Ethnicity and Advanced Breast Cancer Risk
December 8th 2023In a new study examining population attributable risk proportions (PARPs) based on data from over three million screening mammography exams, researchers found that postmenopausal Black women had the highest BMI-related PARP and premenopausal Asian and Pacific Islander women had the highest breast density-related PARP for advanced breast cancer.
Study: Contrast-Enhanced Mammography Changes Surgical Plan in 22.5 Percent of Breast Cancer Cases
December 7th 2023Contrast-enhanced mammography detected additional lesions in 43 percent of patients and led to additional biopsies in 18.2 percent of patients, over half of whom had malignant lesions, according to a study of over 500 women presented at the recent Radiological Society of North America (RSNA) conference.